Belite Bio seeks tinlarebant approval in Singapore, UK and Switzerland
BLTE•Belite Bio filed marketing applications for tinlarebant to treat Stargardt disease type 1 in Singapore, the UK and Switzerland. U.S. and Japanese applications have been accepted for accelerated review, with a U.S. target action date of February 12, 2027.
1. Applications filed
Belite Bio filed marketing applications for tinlarebant to treat Stargardt disease type 1 in Singapore, the UK and Switzerland through the Access Consortium. If authorized, tinlarebant would be the first approved treatment for the disease in those markets. U.S. and Japanese applications have been accepted for accelerated review, and the U.S. target action date is February 12, 2027.
